Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva® in Patients with Relapsed or Refractory Follicular Lymphoma 2022-02-27 18:30
JW Therapeutics Announces Two Appointments to Strengthen R&D Capability and Pipeline Building 2022-01-10 09:30
JW Therapeutics Presents Primary Clinical Response on Carteyva(R) (relmacabtagene autoleucel injection) in Adults with Relapsed/Refractory Follicular Lymphoma in China at the 63rd ASH Annual Meeting 2021-12-15 10:37
JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129 2021-09-27 20:00
JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel Injection At the 24th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) 2021-09-26 20:00
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China 2021-09-06 19:03
JW Therapeutics Announces Strategic Partnership with MediTrust Health 2021-08-20 17:00
JW Therapeutics Presents Data from Pivotal Trial of Relma-cel at the 62nd ASH Annual Meeting 2020-12-07 18:30
Leading Cell Therapy Company JW Therapeutics Lists on Main Board of HKEX 2020-11-03 10:37
1 2